Natera, Inc. Common Stock (NTRA) Valuation
Historical valuation analysis based on 500 data points (2024-09-26 to 2026-09-24)
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT)...
Natera, Inc. Common Stock (NTRA) currently trades at a P/S ratio of 23.13 (range: 9.23–23.13, 100th percentile — expensive relative to its history).
Natera, Inc. Common Stock trades well above its own historical valuation range across most metrics.
Historical Valuation Metrics
| Metric | Current | Min | Median | Max | Percentile | Assessment |
|---|---|---|---|---|---|---|
| P/S Ratio | 23.13 | 9.23 | 12.42 | 23.13 | 100th | expensive relative to its history |
| FCF Yield | 0.00 | 0.00 | 0.00 | 0.01 | 0th | expensive relative to its history |
Natera, Inc. Common Stock (NTRA) Valuation & P/E History
Natera, Inc. Common Stock (NTRA) is a US-listed stock operating in the Healthcare sector, specifically the Services-Medical Laboratories industry currently trading at $409.00 with a market capitalization of $59.0 billion. This page provides historical valuation analysis for NTRA based on 500 data points covering 2024-09-26 to 2026-09-24.. The P/S ratio of 23.13 compares to a median of 12.42.
NTRA Valuation Metrics & Historical Range
The valuation table above shows Natera, Inc. Common Stock's current and historical valuation multiples, including P/E ratio, P/S ratio, EV/EBITDA, FCF yield, and dividend yield. Each metric is compared to its own historical range to determine whether NTRA is currently trading above or below its typical valuation levels.
- P/E ratio: Price-to-earnings measures how much investors pay per dollar of earnings. A P/E above the historical median suggests NTRA is expensively valued; below the median suggests it is cheap.
- P/S ratio: Price-to-sales is useful for companies with volatile or negative earnings. Lower P/S relative to history may indicate value.
- EV/EBITDA: Enterprise value to EBITDA adjusts for debt and cash, providing a capital-structure-neutral valuation measure for Natera, Inc. Common Stock.
- FCF yield: Free cash flow yield shows the cash return relative to market price. Higher yields may indicate undervaluation.
Is NTRA Overvalued or Undervalued?
Natera, Inc. Common Stock trades well above its own historical valuation range across most metrics. The overall valuation percentile of 100 combines P/E, P/S, and EV/EBITDA percentiles into a single measure of how expensive NTRA is relative to its own history. A percentile below 25 suggests the stock may be undervalued, while a percentile above 75 suggests it may be overvalued.
However, valuation is only one factor in investment decisions. A stock can remain "overvalued" for years if growth accelerates, or "undervalued" if the business deteriorates. Always combine valuation analysis with financial statement analysis and the full NTRA analysis page for a complete picture.
Valuation data is computed from historical price and fundamental data via Polygon.io and Finnhub.NTRA trades on NYSE/NASDAQ. This page is for informational purposes only and is not financial advice.